EDGC to ex­pand into Asian mar­ket

BioSpectrum (Asia) - - Company News -

Korea based ge­netic anal­y­sis com­pany, Eone-Di­ag­nomics Genome Cen­ter (EDGC), is plan­ning to ex­pand its business into East Asian mar­ket with Asia’s largest net­work of cord blood and cord lin­ing bank­ing ser­vice provider Cordlife as the com­pany aims to ex­pand its geo­graph­i­cal pres­ence in Asian genome mar­ket. EDGC will ini­tially be­gin to ser­vice its Non-In­va­sive Pre­na­tal Test (NIPT), named “Gen Screen,” to both the Philip­pines and In­done­sia through Cordlife’s sales net­work within each coun­try. In par­tic­u­lar, In­done­sia has the sec­ond high­est birth rate in the world af­ter China. Mak­ing a move into such a coun­try, the com­pany is ex­pected to see a def­i­nite steep growth in sales. The com­pany will then stretch to the other Asian coun­tries in which Cordlife’s high-func­tion­ing work­force is present and pro­vide a wider range of ser­vices later in­clud­ing but not lim­ited to cus­tom­ized ge­netic test (gene2me plus), new­born screen­ing (BeBeGene), oph­thal­mo­logic ge­netic test (myeye­gene) and Di­rect-toCon­sumer (DTC) ge­netic test­ing (gene2me). The com­pany pre­vi­ously came into the spot­light re­cently, upon an­nounc­ing its best-in-class AI backed non-in­va­sive pre­na­tal test, thereby at­tract­ing the at­ten­tion of do­mes­tic and in­ter­na­tional in­dus­tries.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.